In COSAN-exposed HEK293 cells, 100 nM Ivachtin co-treatment reduced blebbing and supported recovery after washout. The experiment tested protection during COSAN exposure and subsequent recovery, rather than Ivachtin monotherapy. [2]
Activity depended on the model and endpoint. In CHO-7W cells, Ivachtin had limited efficacy against cerivastatin-induced APPΔC31 production after 24 h, while Q-VD-OPh strongly reduced the signal. [3]
Caspase-3 potency and substrate-competition characterization
Biochemical assay · Recombinant human caspase-3; Ac-DEVD-AMC fluorogenic substrate [1]
Compound 7a inhibited caspase-3. Substrate variation supported a noncompetitive pattern; reversibility is not adopted.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0–0.8 μM for mechanistic characterization
- Exposure duration
- Initial-velocity measurements; assay exposure time not specified
- Method
- Ac-DEVD-AMC varied from 2–60 μM; standard assay uses 10 μM substrate. Fluorescence excitation/emission 360/460 nm.
- Vehicle
- 5% final DMSO
- Reported limits
- SI buffer sentence is internally malformed and is not reconstructed. SI explicitly lists 5 mM β-mercaptoethanol. Table and kinetic IC50 uncertainty definitions are not supplied.
Methods and source locations
Compound reported in the paper: Ivachtin; Compound label in the paper: 7a
Applies to the named molecular compound; does not validate any Adooq lot.
p. 3682 Table 1, Figures 1–2; SI S12, S14 Figure S1
Caspase-3-catalyzed Ac-DEVD-AMC cleavage: Fluorescence-rate inhibition assay; SI specifies mean of three independent measurements per experimental point. Meaning of the table ± term is not defined. — p. 3682 Table 1, row 7a; SI S12 Enzyme Inhibition Assay
Caspase-3 inhibition across substrate concentrations: Substrate-variation experiment; reported in text, separate from Table 1 estimate; uncertainty type not defined. — p. 3682 text accompanying Figure 1
Substrate dependence of inhibition: Inhibition curves and initial-velocity substrate curves; Lineweaver–Burk representation. — p. 3682 Figures 1–2 and text; SI S14 Figure S1
Caspase panel limits target specificity
Biochemical assay · Recombinant human caspase panel and enzyme-specific substrates [1]
Caspase-3 was the most strongly inhibited enzyme in the panel, but selectivity over other caspases was modest.
Literature-Reported Treatment Conditions
- Treatment concentration
- Incremental inhibitor concentrations; exact panel range not specified in Figure S3 caption
- Method
- Enzyme-specific fluorogenic substrates; time-dependent fluorescence
- Vehicle
- DMSO per shared enzyme-assay methods
- Reported limits
- Per-enzyme substrate concentrations and replicate/error definitions not specified for this panel. Main text describes caspases 1–9; SI graphic also labels caspase-10.
Methods and source locations
Compound reported in the paper: Ivachtin; Compound label in the paper: 7a
Applies to the named molecular compound; does not validate any Adooq lot.
p. 3682 selectivity paragraph; SI S12, S15 Figure S3
Relative inhibitory potency across caspases: pIC50 panel from concentration-response measurements of substrate-cleavage fluorescence; no exact bar values inferred. — p. 3682 selectivity paragraph; SI S15 Figure S3 and caption
Ivachtin co-treatment during COSAN exposure
Cell-based study · Low-density human HEK293 cells exposed to COSAN [2]
Ivachtin co-treatment reduced the blebbing morphology associated with COSAN exposure and supported cell recovery after washout. This is a combination result, without an Ivachtin-alone comparison.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 nM Ivachtin
- Exposure duration
- 24 h co-treatment, then washout and 24 h further growth
- Method
- Ivachtin plus COSAN exposure followed by removal of both agents
- Co-treatment
- 200 μM COSAN
- Reported limits
- Ivachtin supplier/form, vehicle and precise low-density plating number not specified in the relevant source passages. Methods list both direct counting and ATP luminescence for mammalian cells without assigning Figure 1D to a single readout.
Methods and source locations
Compound reported in the paper: Ivachtin
Results apply to the paper’s named Ivachtin reagent in the stated model and combination.
Figure 1C–D and caption; Results mammalian-cell paragraphs; Methods cell-number assessment
Morphology at 24 h and cell density after treatment/washout: Phase-contrast images and cell-density endpoint; Figure 1D shows mean ± SD for 3 independent experiments. Exact bar heights not extracted. — Figure 1C–D and caption; Results mammalian-cell paragraph beginning “For some cells and growth conditions”
Limited inhibition of statin-induced APP cleavage
Cell-based study · CHO-7W cells stably expressing human wildtype APP751 [3]
Ivachtin showed limited efficacy against cerivastatin-induced APPΔC31 production under the tested conditions, whereas the pan-caspase control Q-VD-OPh strongly reduced the signal.
Literature-Reported Treatment Conditions
- Treatment concentration
- Increasing Ivachtin concentrations; plotted upper concentration 30 μM
- Exposure duration
- 24 h
- Method
- Cell co-treatment; APPΔC31 measured by AlphaLISA
- Co-treatment
- 10 μM cerivastatin
- Reported limits
- Ivachtin supplier/form, final vehicle concentration, and S3B-specific replicate/error semantics are not defined in the examined passages. Do not borrow n from other experiments.
Methods and source locations
Compound reported in the paper: Ivachtin
Results apply to the paper’s named Ivachtin reagent in the stated model and combination.
SI Figure S3B and caption; relevant Results paragraph; Methods AlphaLISA and validation
Cerivastatin-induced APPΔC31 production: AlphaLISA of APPΔC31 in cell lysates; Figure S3B viewed. No IC50 or exact percentage inferred. — Results “Validation of Inhibitors of the C-terminal Cleavage of APP”, paragraph beginning “Since APPΔC31”; SI Figure S3B and caption